Kratom has demonstrated significant opioid-like effects, posing high risks of addiction and dependency. The absence of FDA approval for any medical use highlights the lack of validated safety and efficacy. Numerous reports of kratom-related fatalities and severe health complications underscore the urgent need for stringent regulation. Classifying kratom as Schedule I will help mitigate these public health risks